February 9, 2008 -- The China CRO industry received coverage last week, with Chemizon, BioDuro, Medicilon and Pharmaron highlighted as part of the tremendous growth in the industry; the shares of WuXi PharmaTech (NYSE: WX) have been declining, perhaps because of its AppTec acquisition; AsiaPharm Group (SI: ASPH) received a buyout offer from MBK Partners; China Sky One Medical (OTCBB: CSKI) raised $25 million through a private placement; KPMG of the UK expects M&A to decline worldwide in 2008 while JVs rise, though China remains hot; Lotus Pharma (OTCBB: LTUS) reported success for a clinicial trial of a generic angina drug; and China Shenghuo Pharmaceutical Holdings (AMEX: KUN) will market its TCM-based skin care products in the US. More details...
